Latest Astellas Pharma US Inc. Stories
NORTHBROOK, Ill., Dec. 4, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for tacrolimus extended release capsules, for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. Based upon the September receipt of the...
NORTHBROOK, Ill., Nov. 20, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Tarceva(®) (erlotinib) tablets for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor...
NORTHBROOK, Ill., Oct. 22, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that MYRBETRIQ(TM) (mirabegron) extended-release tablets, indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency, is now available through U.S. pharmacies. "The availability of MYRBETRIQ marks an important milestone in our ongoing...
NORTHBROOK, Ill., Sept. 24, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. Developed by Astellas,...
NORTHBROOK, Ill., Sept. 14, 2012 /PRNewswire/ -- More than generosity of spirit drives employees at Astellas Pharma US, Inc. (Astellas Pharma US), a subsidiary of Tokyo-based Astellas Pharma Inc. (Astellas), to participate in the company's annual corporate social responsibility initiative, Changing Tomorrow Day, that wraps up today. A personal connection to the locations and a close tie to the company's mission of improving the lives of patients drive employees to volunteer. For...
WAYNE, N.J., SOUTH SAN FRANCISCO, Calif. and TOKYO, July 23, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), and Astellas Pharma Inc. (TSE: 4503) today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva(®) (erlotinib) tablets to Nexavar(®) (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone. The SEARCH (Sorafenib...
NORTHBROOK, Ill., June 28, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug Administration (FDA) has approved Myrbetriq(TM) (mirabegron) extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. "Myrbetriq is the first oral OAB treatment with a distinct mechanism of action...
KISSIMMEE, Fla., June 13, 2012 /PRNewswire/ -- Give Kids The World Village (GKTW) will host its largest single contingent of volunteers in its history on Wednesday, June 13, when more than 1,300 Astellas Pharma US, Inc. employees trade their iPhones and corporate focus for brushes, rakes and wrapping paper to help make dreams come true for children with life-threatening diseases. In town for the company's annual national sales meeting in Orlando, the Astellas...
DEERFIELD, Ill., April 5, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted that the overall risk/benefit assessment supports approval of mirabegron (YM178) for the treatment of overactive bladder (OAB) (Yes: 7, No: 4, Abstain: 1). Today's committee recommendation, although not...
DEERFIELD, Ill., March 13, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. (Astellas), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) today announced the debut of the Astellas Oncology Cycling Team presented by Athletes By Design (ABD) Cycling. The team is registered as a Domestic Elite Team with USA Cycling and will concentrate on the development of young, up-and-coming riders. The team will compete in the National Criterium Calendar, National Racing Calendar,...
